Genenta Science SpA Sponsored ADR (GNTA)

NASDAQ:GNTA

GNTA

Genenta Science SpA Sponsored ADR

RESEARCH TOOLSreports

Genenta Science SpA Sponsored ADR (GNTA) Price & Analysis

77 Followers

GNTA Stock Chart & Stats

$1.45

$0.22(4.52%)

At close: Jan 08 4:00 PM EST

$1.45

$0.22(4.52%)

Day’s Range― - ―

52-Week Range$0.55 - $10.00

Previous Close$5.5

Volume13.55K

Average Volume (3M)13.18K

Market Cap

$37.49M

Enterprise Value$18.99M

Total Cash (Recent Filing)$28.15M

Total Debt (Recent Filing)$7.60M

Price to Earnings (P/E)―

Beta0.17

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding23,591,020

10 Day Avg. Volume11,250

30 Day Avg. Volume13,183

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)1.14

Price to Sales (P/S)0.00

P/FCF Ratio-3.64

Enterprise Value/Market Cap0.51

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-702.41

Enterprise Value/Ebitda-5.97

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.46

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical ProgressThe company's lead asset, Temferon, is advancing in first-line glioblastoma and has expanded into metastatic renal cell carcinoma, showing progress in its clinical programs.

Regulatory ApprovalGenenta recently received approval from the Agenzia Italiana del Farmaco (AIFA) to initiate this Phase 1 study in mRCC.

Safety ProfileIn the Phase 1/2a trial for glioblastoma, Temferon has been well tolerated with no dose-limiting toxicities, highlighting its safety profile.

Bears Say

Revenue DelaysTimelines for commercialization of Temferon have been pushed back to 2028 in Europe and 2029 in the US, indicating potential delays in revenue generation.

Genenta Science SpA Sponsored ADR News

Genenta Science Closes All-Share Acquisition of Remaining Stake in A.T.C.

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has issued an update. On May 25, 2026, Genenta Science...

12d ago

GNTA

Genenta Science Ends Ospedale San Raffaele License to Refocus Strategy

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has issued an update. On May 18, 2026, Genenta Science’s...

22d ago

GNTA

Genenta Science to Close U.S. Subsidiary and Shift CFO to Consulting Role

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has issued an announcement. Genenta Science S.p.A. said on April...

1M ago

GNTA

Genenta Science Moves Into Aerospace With Majority Investment Deal for Sòphia High Tech

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has issued an update. On April 22, 2026, Genenta Science...

2M ago

GNTA

Genenta Science Warned by Nasdaq Over Minimum Bid Price Compliance

Genenta Science SpA Sponsored ADR ( ($GNTA) ) just unveiled an announcement. On April 10, 2026, Genenta Science...

2M ago

GNTA

Genenta Moves to Acquire Control of Italian Space-Defense Supplier Sòphia High Tech

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has shared an update. On March 25, 2026, Genenta signed...

3M ago

GNTA

Genenta Science enters binding offer to fund Sophia High Tech

Genenta Science (GNTA) announced that it has entered into a binding offer with Sophia High Tech, under which...

3M ago

GNTA

Genenta Science Cancels Late-March Vote on Rebrand to Saentra Forge

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has issued an update. Genenta Science S.p.A., an Italian biotechnology...

3M ago

GNTA

Genenta continues to evaluate options for original biotechnology platform

Genenta Science (GNTA) announced that, with respect to its biotechnology platform, Genenta has been and continues to be...

3M ago

GNTA

Genenta to Rebrand as Saentra Forge and Pivot into Italian National-Security Industrial Consolidator

Genenta Science SpA Sponsored ADR ( ($GNTA) ) has shared an update. On January 27, 2026, Genenta Science...

4M ago

GNTA

Genenta Science to Rebrand as Saentra Forge and Enters Defense Sector with A.T.C. Stake, While Suing Enea Tech Biomedical

The latest announcement is out from Genenta Science SpA Sponsored ADR ( ($GNTA) ). In a strategic shift...

4M ago

GNTA

Genenta Science to change name to Saentra Forge, seeks controlling stake in ATC

Genenta Science (GNTA) intends to target majority ownership in companies with established operating profitability, typically generating up to...

4M ago

GNTA

Genenta Science provides update from TEM-GBM study

Genenta Science (GNTA) announced an update from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme patients with...

7M ago

GNTA

Genenta Science Expands Board and Corporate Purpose Following Shareholders’ Meeting

Genenta Science SpA Sponsored ADR ( ($GNTA) ) just unveiled an update. On October 29, 2025, Genenta Science...

7M ago

GNTA

GNTA FAQ

What was Genenta Science SpA Sponsored ADR’s price range in the past 12 months?

Genenta Science SpA Sponsored ADR lowest stock price was $0.55 and its highest was $10.00 in the past 12 months.

What is Genenta Science SpA Sponsored ADR’s market cap?

Genenta Science SpA Sponsored ADR’s market cap is $37.49M.

When is Genenta Science SpA Sponsored ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Genenta Science SpA Sponsored ADR’s earnings last quarter?

Currently, no data Available

Is Genenta Science SpA Sponsored ADR overvalued?

According to Wall Street analysts Genenta Science SpA Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genenta Science SpA Sponsored ADR pay dividends?

Genenta Science SpA Sponsored ADR does not currently pay dividends.

What is Genenta Science SpA Sponsored ADR’s EPS estimate?

Genenta Science SpA Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genenta Science SpA Sponsored ADR have?

Genenta Science SpA Sponsored ADR has 23,591,020 shares outstanding.

What happened to Genenta Science SpA Sponsored ADR’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Genenta Science SpA Sponsored ADR?

Currently, no hedge funds are holding shares in GNTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Genenta Science SpA Sponsored ADR Stock Smart Score

Underperform

News Sentiment

Neutral

Bullish news 50%
Bearish news 50%

Technicals

Fundamentals

Return on Equity

-36.82%

Trailing 12-Months

Asset Growth

143.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genenta Science SpA Sponsored ADR

Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.